Tune & Track
Affinity Tuned CAR T Cells for Solid Tumors
Unlocking the Full Potential of CAR T Cell Therapies
AffyImmune is harnessing the power of the body’s own immune system to seek and destroy cancer cells by overcoming the immunotherapy challenges for solid tumors. AffyImmune’s proprietary “Tune & Track” technology enhances the ability of a patient’s own immune cells to attack and destroy solid tumors, while avoiding damage to normal cells and tissues.
Science
Our core focus is on fine-tuning the affinity of CAR T cells to selectively kill tumor cells while sparing healthy cells to prevent toxicity and ensuring more natural, robust, and long-lasting activity of the CAR T cells. We engineer our CAR T cells to be monitorable in real-time in patients during treatment.
FEATURED NEWS
FEATURED JOBS
AffyImmune Therapeutics Adds Serial Entrepreneur Robert Forrester to Board of Directors
NATICK, Mass. (SEPTEMBER 29, 2022) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment of solid cancers, announced today that serial biotech entrepreneur Robert Forrester has been appointed to its [...]
Scientist, Analytical Development
AffyImmune Therapeutics (“Affy”), a clinical stage biotechnology company focused on developing technologies that expand the utility and improve the safety and efficacy of cell-based immunotherapy for cancer, is seeking an Analytical Development Scientist to help advance the use of CAR T therapy for [...]